Seagen Inc. (SGEN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Bothell, WA, United States. The current CEO is David R. Epstein.
SGEN has IPO date of 2001-03-09, 3,256 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $43.15B.
Seagen Inc. is a biotechnology company headquartered in Bothell, Washington, specializing in the development and commercialization of cancer therapies. The company's commercial portfolio includes ADCETRIS for Hodgkin lymphoma and CD30-positive T-cell lymphomas, PADCEV for advanced urothelial cancer, and TUKYSA for HER2-positive breast cancer, alongside several pipeline candidates such as TIVDAK for cervical cancer and multiple novel antibody-drug conjugates targeting various oncology indications. Seagen operates globally and maintains strategic collaboration agreements with leading pharmaceutical companies including Takeda, Merck, and Genmab. The company was founded in 1997 as Seattle Genetics and rebranded as Seagen Inc. in 2020.
